

November 13, 2007



Kane Biotech Inc.: DispersinB(TM) Biofilm Patent Issued in the United States

WINNIPEG, MANITOBA -- (MARKET WIRE) -- 11/13/07 -- Kane Biotech Inc. (TSX VENTURE: KNE), a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms, is pleased to announce the issuance of Patent No. 7,294,497 entitled "Compositions and Methods for Enzymatic Detachment of Bacterial Biofilms", by the US Patent and Trademark Office. This patent protects DispersinB(TM), the Company's core technology, and its use in treating infections caused by biofilms. DispersinB(TM) can be used in human, animal, plant and industrial applications.

"This patent is the foundation of our biofilm intellectual property estate," stated Mr. Gord Froehlich, President and CEO, Kane Biotech. "In addition to having this key patent issued we have numerous additional patent applications pending for various antimicrobial combinations with DispersinB(TM)."

The patent stands on a base of solid scientific evidence that DispersinB(TM) both inhibits and destroys biofilms. This evidence comes from research conducted at Baylor College of Medicine, Houston, Texas; Southwest Regional Wound Care Center in Lubbock, Texas; Harvard-MIT, Boston, Massachusetts; University of Medicine and Dentistry of New Jersey; Department of Health and Technology in Italy; and in-house at Kane Biotech.

Biofilms are a major cause of a number of serious medical problems including chronic infections in humans and animals and medical device related infections. They develop on surfaces such as catheters and prosthetic implants, inner ears, teeth, gums, lungs and the urogenital tract. Biofilms are pervasive and costly to deal with, as evidenced by the fact that approximately 80% of all human bacterial infections involve biofilms and the healing of chronic wounds costs the United States health care system \$20 Billion per year. Biofilms also pose major problems in industry as they grow on surfaces of water tanks, pipes, and food processing containers and are difficult and costly to remove.

DispersinB(TM) is a novel enzyme capable of both inhibiting and dispersing bacterial biofilms. Kane Biotech has a worldwide exclusive license to all human, animal and industrial applications of DispersinB(TM) from the University of Medicine and Dentistry of New Jersey. Kane Biotech is presently using DispersinB(TM) alone, and in combination with other antimicrobial agents, to develop a wound care therapy and a proprietary medical device coating.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other

microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.

Kane Biotech Inc. uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Kane's early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers' willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Kane's filings with Canadian securities regulatory authorities, as well as Kane's ability to anticipate and manage the risks associated with the foregoing. Kane cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Kane's forward-looking statements to make decisions with respect to Kane, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Kane cannot provide assurance that actual results will be consistent with these forward-looking statements. Kane undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contacts:

Kane Biotech Inc.

Justin Gagnon

Manager, Investor Relations

(204) 478-5602

(204) 453-1314 (FAX)

Email: jgagnon@kanebiotech.com

Website: www.kanebiotech.com